MannKind(MNKD) - 2025 Q2 - Quarterly Results

Conference call today at 9:00 am ET DANBURY, Conn. and WESTLAKE VILLAGE, Calif. August 6, 2025 (Globe Newswire) — MannKind Corporation (Nasdaq: MNKD) today reported financial results for the second quarter 2025 and provided a business update. "The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "In our o ...